Peritonitis News and Research

RSS

Peritonitis is an inflammation of the peritoneum, the serous membrane which lines part of the abdominal cavity and viscera. Peritonitis may be localized or generalized, and may result from infection (often due to rupture of a hollow organ as may occur in abdominal trauma or appendicitis) or from a non-infectious process.

Location matters for inflammation clearance

Health conditions that involve inflammation run the gamut, from multiple sclerosis and lupus to arthritis, diabetes, and cancer. While inflammation can serve as a normal response to help the body deal with injury or infection, problems arise when it persists, potentially harming surrounding tissues.

20 Nov 2018

Abdominal pain should be seen as a warning sign for invasive meningococcal disease

Patients with meningococcal infection generally develop symptoms including a high temperature, vomiting and a stiff neck... but they might also just have a bad stomach ache. This can be so severe that they are sometimes wrongly operated for appendicitis.

26 Apr 2018

Study: One-third of bacterial infections in patients with cirrhosis induced by MDR bacteria

A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant bacteria of 34% and significant regional differences in the risk of developing a multi-drug-resistant infection.

13 Apr 2018

New class of antimicrobial polymers can kill five hard-to-treat multidrug-resistant bacteria

An international research team led by the Institute of Bioengineering and Nanotechnology of the Agency for Science, Technology and Research and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects.

7 Mar 2018

New study suggests potential new therapeutic approach to septic shock recovery

A new study published online in the Journal of Leukocyte Biology suggests a new approach to treating patients with sepsis, one of the most frequent causes of morbidity and mortality in intensive care units.

1 Jun 2017

Study highlights importance of sex-specific differences in complex biological processes

New research published in the Journal of Leukocyte Biology shows that male and female mice respond differently to inflammation at the cellular level. Specifically, in male mice the spleen acts as a source of white blood cells, while in females this is not the case. This discovery suggests that human studies are necessary to determine if current medical practices, which treat men and women generally the same, should be altered to reflect sex-specific differences.

3 Nov 2015

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, announced the presentation of results demonstrating the synergistic antibacterial activity of its lead clinical candidate, TXA709, when combined with cefdinir, a third-generation cephalosporin antibiotic.

19 Sep 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders.

30 Jan 2015

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.

19 Aug 2014

Health Canada offers tips on proper use of topical antiseptics to reduce infections

Health Canada is reminding healthcare professionals, caregivers and consumers of the safe use of topical antiseptics used to clean the skin before an operation (preoperative) or before an injection (preinjection).

26 Jul 2014

Patients undergoing peritoneal dialysis catheter placement experience fewer complications

Patients undergoing peritoneal dialysis catheter placement via fluoroscopy and ultrasound-guidance experienced significantly fewer complications at 1 year post-insertion than did patients whose catheters were placed laparoscopically.

8 May 2014

Invasive pneumococcal disease in Taiwan on the wane, but threats remain

The incidence of invasive pneumococcal disease in Taiwan has decreased significantly in recent years, study findings indicate.

17 Feb 2014

New discovery has potential to transform heart attack treatments

An Australian discovery has the potential to transform the treatment of a heart attack, after a new approach boosted heart function and reduced heart scarring in preclinical studies.

16 Jan 2014

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Treating bacteria with silver compounds boosts efficacy of old antibiotics

Slipping bacteria some silver could give old antibiotics new life, scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University reported June 19 in Science Translational Medicine.

20 Jun 2013

Sorrento Therapeutics' anti-MRSA program gets NIAID support

Sorrento Therapeutics, Inc. announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus, was renewed for the second year of a two year Phase I grant award.

18 May 2013

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.

8 May 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013